How does immunoglobulin G3 (IgG3) regulate immune responses in HIV-infected individuals by interfering with B-cell receptor function?

1. What is the central role of B cell receptor signaling in adaptive immune responses?

B cells are key effector cells of the adaptive immune system, specifically recognizing and binding foreign antigens (such as viruses and bacteria) through their surface B cell receptors (BCR). This binding triggers BCR-mediated signal cascades, driving B cell activation, clonal expansion, antibody class switching, and differentiation into plasma cells, thereby producing large quantities of high-affinity specific antibodies. These antibodies can neutralize pathogens, mediate opsonophagocytosis, or activate the complement system, forming the basis for infection clearance and immune memory establishment. In pathological states like chronic viral infections (e.g., HIV), maintaining normal B cell function is crucial for controlling the virus and preventing opportunistic infections.

2. What are the characteristics of B cell dysfunction in the context of HIV infection?

HIV infection not only directly attacks CD4+ T cells but also causes widespread immune system dysfunction, including disturbances in B cell homeostasis. In HIV-infected individuals, B cell dysfunction is often observed, manifesting as polyclonal B cell activation, impaired specific antibody responses, altered memory B cell pools, and weakened responses to vaccination. These abnormalities are partly attributed to persistent immune activation, altered inflammatory cytokine environments, and direct interference by viral proteins. However, the precise molecular mechanisms underlying the suppression of BCR signaling itself remain incompletely understood. Recent studies reveal that a specific type of antibody—immunoglobulin G3 (IgG3)—may play an unexpected key role in B cell functional suppression in HIV-infected individuals.

3. What are the specific patterns of IgG3 expression on B cells in HIV-infected individuals?

To investigate the impact of HIV infection on B cells, researchers compared peripheral blood B cell characteristics between HIV-infected and uninfected individuals. The study found that immunoglobulin G3 (IgG3) was abnormally present on the surface of B cells in HIV-infected individuals, whereas it was not observed in uninfected individuals.

This abnormal expression exhibits significant population specificity and disease stage dependence. The study found that in individuals with high viral loads, chronic untreated HIV infection, IgG3 expression on B cell surfaces was particularly prominent and more common among African American or African descent populations. When infected individuals began effective antiretroviral therapy and achieved viral suppression, IgG3 expression on B cells decreased or disappeared. These associations strongly suggest that IgG3 accumulation on B cells is closely related to persistent and active HIV replication, possibly representing part of the immune regulatory response to chronic viral infection.

4. How does IgG3 specifically interfere with normal B cell receptor function?

Mechanistic studies show that IgG3 on B cell surfaces does not bind foreign antigens in the traditional antibody form but instead interacts directly with the BCR itself. This "self-trans" binding mode causes the Fc or Fab regions of IgG3 to occupy the antigen-binding site of the BCR or associate closely with it, physically blocking the normal binding of BCR to its specific pathogen antigens.

This blockade has profound biological consequences: it prevents BCR from effectively transmitting activation signals, rendering B cells sluggish or unresponsive to specific antigen stimulation. Even in the presence of pathogens (e.g., HIV or opportunistic pathogens), B cells struggle to activate fully, proliferate, and produce high levels of neutralizing antibodies. Thus, abnormal IgG3 presence on B cells acts as a "molecular brake" at the initiation stage of immune responses. While this may aim to suppress excessive immune activation and inflammatory damage caused by HIV infection (a possible compensatory regulation), it also severely weakens the body's ability to generate effective protective antibody responses, contributing to immunodeficiency.

5. What is the key application value of LGG3 F(c) recombinant rabbit monoclonal antibody in research?

To deeply analyze the mechanism of IgG3-mediated B cell functional suppression, especially to clarify its interacting domains with BCR, highly specific and high-affinity research tools are essential. Recombinant rabbit monoclonal antibodies targeting the IgG3 Fc fragment are indispensable in such studies:

1. Specific detection and quantification: These antibodies can be used in flow cytometry, immunofluorescence, or Western Blot to specifically detect and quantify IgG3 Fc presence and levels on B cell surfaces or in body fluids, clarifying expression patterns and serving as potential biomarkers for disease activity or treatment response.

2. Functional blockade studies: In vitro functional experiments, these antibodies can pre-block IgG3 Fc on B cell surfaces to observe whether BCR responsiveness to specific antigens is restored, directly validating the hypothesis that IgG3 mediates suppression via its Fc region.

3. Co-immunoprecipitation and interaction analysis: Using these antibodies for co-immunoprecipitation can specifically pull down protein complexes interacting with IgG3 Fc from lysates of HIV-infected B cells. Combined with mass spectrometry, this helps identify other potential interaction partners beyond BCR, mapping the IgG3-mediated suppression network comprehensively.

4. Exploring therapeutic interventions: Based on the above mechanisms, developing neutralizing antibodies or small molecules to block IgG3-BCR interactions is a potential therapeutic strategy. LGG3 F(c) recombinant rabbit monoclonal antibodies can serve as key tools to validate such strategies, e.g., assessing whether candidate drugs competitively inhibit antibody binding to B cells.

6. Which manufacturers provide LGG3 F(c) recombinant rabbit monoclonal antibodies?

Hangzhou Starter Biotechnology Co., Ltd. has independently developed the "Human IgG3 Fc Recombinant Rabbit mAb (HRP Conjugate)" (product name: Human IgG3 Fc Recombinant Rabbit mAb (HRP Conjugate) (S-459-75), catalog number: S0B1502). This product is a high-subtype-specific, highly sensitive, and stable detection and quantification tool. Developed using recombinant rabbit monoclonal antibody technology and conjugated with high-activity horseradish peroxidase (HRP), it plays a critical role in human IgG subtype detection, antibody drug quantification, and immune complex research.

 Technical support: We provide detailed product technical documentation, including subtype cross-reactivity validation data, recommended experimental conditions (e.g., ELISA coating and blocking protocols), application examples across different platforms, and professional technical consultation, fully supporting customers in achieving accurate and reliable results in immunological analysis and biopharmaceutical development.

Hangzhou Starter Biotechnology Co., Ltd. is committed to providing high-quality, high-value biological reagents and solutions for global innovative pharmaceutical companies and research institutions. For more information about the "Human IgG3 Fc Recombinant Rabbit mAb (HRP Conjugate)" (catalog number S0B1502) or to request a sample test, please contact us.

Product Information